Newly Granted US Composition of Matter Patent Extends Exclusive Protection for VBL Therapeutics' Lead Drug Candidate VB-111 Until October 2033
December 01, 2015 at 08:04 AM EST
VBL Therapeutics (NASDAQ: VBLT), today announced the grant of US Patent No. 9,200,056, entitled "A Fas-Chimera Adenovirus Vector" by the ...
